Sanara MedTech Inc. SMTI Commissions and Contract Termination Costs
Commissions and Contract Termination Costs at other companies
Other financials
Where this comes from
Reported directly by Sanara MedTech Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedSalesCommissionCurrent.
The official record: Sanara MedTech Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sanara MedTech Inc.'s commissions and contract termination costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sanara MedTech Inc.'s commissions and contract termination costs?
- Sanara MedTech Inc. (SMTI) reported commissions and contract termination costs of $9.08M in Q1 2026.
- How has Sanara MedTech Inc.'s commissions and contract termination costs changed year-over-year?
- Sanara MedTech Inc.'s commissions and contract termination costs increased by 10.6% year-over-year, from $8.21M to $9.08M.
- What is the long-term trend for Sanara MedTech Inc.'s commissions and contract termination costs?
- Over 5 years (2020 to 2025), Sanara MedTech Inc.'s commissions and contract termination costs has grown at a 37.3% compound annual growth rate (CAGR), from $2.42M to $11.78M.
- What does commissions and contract termination costs mean?
- This represents the accrued liability for sales commissions earned by the sales force and costs associated with the early termination of contractual agreements. It reflects short-term obligations tied to sales performance and strategic restructuring activities. Monitoring this helps investors assess the company's sales incentive structure and potential one-time costs related to operational shifts.